Xenetic Biosciences, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019; filed May 10, 2019. Xenetic is a development-stage biopharmaceutical company focused on oncology therapeutics and biologic-drug technologies. Its lead drug candidate is XBIO-101; it also has the PolyXen platform and agreed to acquire the XCART personalized CAR T-cell platform.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | No revenue reported | No revenue reported under the disclosed collaborations |
| Research and development expense | $463,782 | $706,271; down 34.3% |
| General and administrative expense | $863,373 | $1,122,072; down 23.1% |
| Operating loss | $1,327,155 | $1,828,343 |
| Net loss | $1,327,250 | $1,822,518 |
| Net loss applicable to common stockholders | $5,206,697, including a $3,879,447 deemed dividend | $1,822,518 |
| Basic and diluted loss per share | $0.54 | $0.21 |
| Cash used in operating activities | $1,254,522 | $1,666,803 |
Margins are not meaningful because the filing reports no revenue. At March 31, 2019, cash was $2.02 million, restricted cash was $66,510, current assets were $3.20 million, and current liabilities were $2.01 million. The company reported working capital of approximately $1.2 million, versus a $0.4 million deficit at December 31, 2018. Total liabilities were $4.94 million; the balance sheet presents no conventional borrowing line. The filing notes a $150,000 loan to be repaid in connection with the XCART transaction.
Cash and restricted cash increased by $1.45 million in the quarter, primarily reflecting $2.70 million of net proceeds from a registered direct offering, partly offset by operating cash use. No cash-flow or profitability guidance was provided. Management estimated that existing resources would fund planned operations, obligations, and commitments only through the first half of 2019.
Material developments and period-over-period changes
- Lower R&D expense primarily reflected reduced XBIO-101 Phase II trial spending. Patient enrollment in the trial closed in March 2019 after slower-than-expected progress associated with enrollment and retention challenges.
- Lower G&A reflected reduced payroll and share-based expense and lower facility costs following the January headquarters relocation, partly offset by higher consulting costs.
- The March offering generated $2.7 million net proceeds. It included 1,040,000 common shares and pre-funded warrants for 509,000 shares, plus accompanying warrants exercisable at $2.25 per share beginning September 2019. The offering triggered the Series B preferred stock down-round provision and a $3.9 million deemed dividend, increasing loss attributable to common stockholders but not the reported net loss.
- The XCART acquisition agreement, signed March 1, remained subject to customary conditions, sufficient post-closing financing, and stockholder approval. Consideration includes 4,875,000 shares to Hesperix sellers, plus 1,968,750 shares to OPKO and 656,250 shares to the Scripps Research Institute under related assignment arrangements. Closing was expected in the first half of 2019. The transaction was expected to be accounted for as an asset acquisition; $0.5 million of related costs had been capitalized.
- The company adopted lease accounting in Q1, recording approximately $43,000 of right-of-use assets and lease liabilities; management said adoption did not materially affect the financial statements.
Outlook, risks, and other disclosures
Management said continued losses are expected and that additional capital or strategic alternatives are needed in the very near term. Xenetic had no committed additional financing. Failure to obtain funding could require cuts or suspension of clinical and preclinical programs, further expense reductions, asset or technology dispositions, or cessation of operations; the filing states that substantial doubt exists about the company’s ability to continue as a going concern. Management’s financing options include equity or debt financing, collaborations, related-party funding, and licensing, but timing and availability are uncertain.
The company planned to focus on XBIO-101 and preliminary XCART development, subject to funding, and to seek partnerships or out-licensing opportunities. No drug candidate had marketing authorization. XCART’s acquisition and development, clinical progress, financing availability, potential dilution, and dependence on collaborators and licensing revenue are key risks. More than 90% of milestone and sublicense revenue received historically came from one collaborator, Takeda. Management reported effective disclosure controls and no material change in internal control; no material legal proceedings or material changes to previously disclosed risk factors were reported.
Investor verification checklist
- Confirm subsequent financing, cash runway, and whether management’s first-half 2019 funding estimate was met.
- Verify whether the XCART transaction closed, all required approvals and financing conditions were satisfied, and the planned share consideration was issued.
- Track XBIO-101 trial status and the effect of enrollment and retention challenges on development plans.
- Review the potential dilution and terms associated with preferred-stock conversion rights, pre-funded warrants, and offering warrants.
- Assess whether licensing, collaboration, or other revenue materialized, given the absence of Q1 revenue and historical reliance on Takeda.